BOTH — Bioethics Income Statement
0.000.00%
Last trade - 00:00- $1.42m
- $1.90m
- 16
- 44
- 32
- 21
Annual income statement for Bioethics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 0.07 | 0.075 | 0.059 | 0.047 | 0.05 |
| Operating Profit | -0.07 | -0.075 | -0.059 | -0.047 | -0.05 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.102 | -0.119 | -0.107 | -0.093 | -0.097 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.102 | -0.119 | -0.107 | -0.093 | -0.097 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -0.102 | -0.119 | -0.107 | -0.093 | -0.097 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.102 | -0.119 | -0.107 | -0.093 | -0.097 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.093 | -0.105 | -0.094 | -0.082 | -0.086 |